USE OF COMBINED NUCLEOTIDE DRUG IN TREATMENT OF OPHTHALMIC MANIFESTATIONS OF SJOGREN’S DISEASE

Abstract

Ophthalmic lesions in Sjogren's disease are among the most pronounced, they significantly complicate the patient's life. Along with Sjogren's disease, there is the so−called Sjogren's syndrome, which is a similar lesion of the salivary and lacrimal glands, which develops in 5−25 % of the patients with systemic connective tissue diseases and in 50−75 % with chronic autoimmune diseases. The main sign of damage to the lacrimal glands is the development of dry keratoconjunctivitis, which in severe cases can lead to complications in the form of corneal ulcers, up to the threat of perforation. The study of the effectiveness of various drugs in the treatment of symptomatic therapy showed that the problem of achieving a lasting effect of correction of ophthalmic manifestations has not been currently solved. In order to study the effectiveness of the drug "Encad−Biolik®" (Kharkiv, Ukraine) to stimulate the reparative processes of the cornea as part of the complex therapy of Sjogren's disease were examined 15 patients (30 eyes) who received the drug "Encad−Biolik®" in the form of intramuscular injections and bath phonophoresis. The duration of treatment was 8.0 days, the time of complete epithelialization of the cornea made 7.4 days. In the eyes of two patients who had corneal ulcers, the process was stopped, resulting in a slight cloud−like turbidity. The results of the study demonstrate that the use of the drug "Encad−Biolik®" in the patients with Sjogren's disease was not accompanied by side effects and reduced the duration of corneal epithelialization, duration of treatment, and improved structural results in corneal healing. Key words: Sjogren's disease, "Encad−Biolik®", cornea, epithelialization.